Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.

PloS one - 15 Feb 2010

Huijgen Roeland, Kindt Iris, Verhoeven Sjoerd B J, Sijbrands Eric J G, Vissers Maud N, Kastelein John J P, Hutten Barbara A

Abstract excerpt

BACKGROUND: The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the present study, we dete...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Apolipoproteins B
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperlipoproteinemia Type II

Share to Netherlands

Share to Outcome Assessment, Health Care

Share to Receptors, LDL

Share to Surveys and Questionnaires

Source

Open in PubMed Open full text

Identifiers

PMID: 20169164
DOI: 10.1371/journal.pone.0009220
PMCID: PMC2821409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20169164-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.PMID 20169164Read ↗

Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.Semantic proximity Read ↗

Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014).Semantic proximity Read ↗

Clinical characteristics and lipid management of patients with familial hypercholesterolemia: results from a 7 years single-centre experience.Semantic proximity Read ↗

Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study.Semantic proximity Read ↗

Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening.Semantic proximity Read ↗

Cascade screening amplifies familial hypercholesterolaemia detection after clinically guided next- generation sequencingSemantic proximity Read ↗

Cascade screening and treatment of children with familial hypercholesterolemia in Turkey.Semantic proximity Read ↗

Lipid Screening, Action, and Follow-up in Children and Adolescents.Semantic proximity Read ↗

A 20-year follow-up study of patients who have been diagnosed with familial hypercholesterolemia in their youthSemantic proximity Read ↗

Cascade screening for familial hypercholesterolemia: Practical consequences.Semantic proximity Read ↗

Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.Semantic proximity Read ↗

Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.